gesunheitpfleges.org



GeoVax Labs expands its HIV/AIDS vaccine program with NIAID, NIH and HVTN

March 21, 2016

"For years, the HIV vaccine field has been working with vaccines that elicited immune responses that primarily controlled immunodeficiency virus challenges in infected animals, but did not actually prevent infections. The ultimate goal is to prevent infections.  The co-expression of GM-CSF with the SIV proteins is a vaccine design that appears to be a large step towards reaching this goal," said Dr. Harriet Robinson, Chief Scientific Officer at GeoVax.  "In our trials in nonhuman primates, GM-CSF enhanced the quality of the SIV-specific antibody response.  Antibody is present in blood and tissues and has the potential of blocking SIV before it infects cells.  The GM-CSF-adjuvanted vaccine induced the production of antibodies characterized with increased tightness of antibody binding.  The tightness of antibody binding, known as avidity, can be expressed as an index.  Animals with indices above 40 were protected from infection, whereas animals with lower indices were infected with the number of challenges to infection correlating with their index."

"We are very pleased that the HVTN will be conducting trial HVTN 094 of our GM-CSF adjuvanted vaccine product, which we expect will begin late this year," said Dr. Robert McNally, CEO of GeoVax.  "The HVTN, funded by the NIAID, is the largest worldwide clinical trials network dedicated to the development and testing of HIV/AIDS vaccines.  We are looking forward to working with an excellent team of HVTN trial investigators."

SOURCE GeoVax Labs, Inc.